Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Alimera Data Will Feature in Scientific Programming at Upcoming Annual Congress

Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision
byBenzinga Newsdesk
April 20, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Alimera Sciences, Inc. (NASDAQ:ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that ILUVIEN® will be highlighted in four posters to be presented at the annual Association for Research in Vision and Ophthalmology (ARVO) conference being held in New Orleans, Louisiana from April 23-27, 2023.

 

Key ILUVIEN Abstracts (presented as posters):

  • Veeral Sheth, M.D., “Long Term Outcomes in Eyes Requiring IOP Lowering Surgery After Treatment with the 0.19 mg Fluocinolone Acetonide Implant for DME: The PALADIN Study”

     

  • Jorge Fortun, M.D., “Long Term Outcomes in Eyes Requiring IOP Lowering Surgery After Treatment with the 0.19 mg Fluocinolone Acetonide Implant for DME: The PALADIN Study”

     

  • Joseph Coney, M.D. and Sarah Godel, “Long Term Outcomes in Eyes Requiring IOP Lowering Surgery After Treatment with the 0.19 mg Fluocinolone Acetonide Implant for DME: The PALADIN Study”
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca, Swedish Orphan Biovitrum And Sanofi Have Updated And Simplified Their Contractual Arrangements Relating To The Development And Commercialization Of Nirsevimab In The US

By Charles Gross
April 11, 4:52 AM
AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given the upcoming launch of nirsevimab in the US and other markets, simplification of the prior arrangements clarifies the roles and responsibilities of relevant parties.   

AZN